Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NONOP2, or "non-POU domain containing, octamer-binding pseudogene 2," is a genetic locus classified as a pseudogene, meaning it does not encode a functional protein product[5][9][7]. It should not be confused with NONO (Non-POU domain containing octamer-binding protein), which is a functional gene of the same family with documented roles in gene regulation and as a potential biological target in cancer and other pathologies[1][2][6]. The NONOP2 gene does not have significant biological function, nor is it classified as a receptor, enzyme, transporter, or therapeutic target. There is no evidence that NONOP2 is involved in disease biology, interacts with drugs, or serves as a biomarker or safety concern. If your intent was to study the functional NonO protein (NONO), whose abbreviation could easily be confused with NONOP2, consult sources on "NONO" instead[1][2][6][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on non-POU domain containing, octamer-binding pseudogene 2 (NONOP2).